133 Molesworth Street
PO Box 5013
Wellington 6140
New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz
16 January 2023
Athina Andonatou
By email: f
[email address]
Ref: H2022018890
Tēnā koe Athina
Response to your request for official information
Thank you for your request under the Official Information Act 1982 (the Act) to Manatū Hauora
(the Ministry of Health) on 21 December 2022. Please find a response to each part of your
request below:
Is the Minister aware of Pfizer's own document "5.3.6 CUMULATIVE ANALYSIS OF POST-
AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2)
RECEIVED THROUGH 28-FEB-2021" dmoanon.com/pdfs/5.3.6-pfizer-Adverse-Event-
Reports.pdf
Manatū Hauora understands that the report,
Cumulative Analysis of Post-Authorization Adverse
Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021, (hereafter
referred to as the Cumulative Analysis Report) was prepared by Pfizer as a part of its
application to the Food and Drug Administration (FDA) in the United States for its Biologics
License Application (BLA) for the Comirnaty COVID-19 vaccine. The BLA process followed the
FDA earlier granting Emergency Use Authorization (EUA) for the use of the vaccine in
December 2020. There is more information about the BLA process at:
www.fda.gov/vaccines-
blood- biologics/development-approval-process-cber/biologics-license-applications-bla-process-
cber.
As the Cumulative Analysis Report was prepared by Pfizer for a specific legal purpose for the
FDA in the United States, Pfizer did not provide it to either Manatū Hauora or Medsafe as the
BLA process does not exist in New Zealand.
However, I can advise that as a part of the provisional consent for the Comirnaty COVID-19
granted in New Zealand under the Medicines Act 1981, Pfizer has provided the same data,
albeitin a form that meets the company’s legal obligations in New Zealand.
Are all doctors, medical professionals and the general population aware of the 9 pages of
adverse effects stated in Pfizer's own document "5.3.6 CUMULATIVE ANALYSIS OF
POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2)
RECEIVED THROUGH 28-FEB-2021" dmoanon.com/pdfs/5.3.6-pfizer-Adverse-Event-
Reports.pdf and if not why not?
The conclusions of the Cumulative Analysis Report are consistent with the information and data
provided by Pfizer to Medsafe as a part of its provisional consent obligations in New Zealand.
As Pfizer had met all theconditions required under the initial consent granted in February 2021,
the provisional consent was renewed for a further two years on 28 October 2021. The renewed
consent requires Pfizer tocontinue to provide data and analysis about the global administration
of the vaccine. There is more information at:
www.health.govt.nz/news-media/news-
items/medsafe-renews-covid-19- vaccine-provisional-approval.
Please provide all documents, meeting minutes, emails, and any other correspondence
between the Ministry of Health, The Prime Minister and Medsafe where this document has
been discussed.
This part of your request is refused under section 18(e) of the Act, as the information requested
does not exist.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions
made under this request. The Ombudsman may be contacted by email at:
[email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Manatū Hauora website at:
www.health.govt.nz/about-ministry/information-releases/responses-
official-information-act-requests.
Nāku noa, nā
Chris James
Group Manager
Medsafe
Page 2 of 2